Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
Month: March 2020
ObsEva Provides Update Related to COVID-19 Pandemic
Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20,…
Year End 2019 Financial Results 05 March 2020
ObsEva SA Link to Annual Report 2019
Geneva, Switzerland and Boston, MA – March 5, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
Annual Report 2019
ObsEva Announces Year End 2019 Financial Results and Business Update
Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3…